Download MendeleyIdentification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
Vazquez, M.L., Kaila, N., Strohbach, J.W., Trzupek, J.D., Brown, M.F., Flanagan, M.E., Mitton-Fry, M.J., Johnson, T.A., TenBrink, R.E., Arnold, E.P., Basak, A., Heasley, S.E., Kwon, S., Langille, J., Parikh, M.D., Griffin, S.H., Casavant, J.M., Duclos, B.A., Fenwick, A.E., Harris, T.M., Han, S., Caspers, N., Dowty, M.E., Yang, X., Banker, M.E., Hegen, M., Symanowicz, P.T., Li, L., Wang, L., Lin, T.H., Jussif, J., Clark, J.D., Telliez, J.B., Robinson, R.P., Unwalla, R.(2018) J Med Chem 61: 1130-1152
- PubMed: 29298069
- DOI: https://doi.org/10.1021/acs.jmedchem.7b01598
- Primary Citation of Related Structures:
6BBU, 6BBV - PubMed Abstract:
Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis. As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling ...
